{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T05:19:31Z","timestamp":1793164771167,"version":"4.5.0"},"reference-count":63,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T00:00:00Z","timestamp":1659312000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T00:00:00Z","timestamp":1659312000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,3,26]],"date-time":"2022-03-26T00:00:00Z","timestamp":1648252800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","journalofsubstanceabusetreatment.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Substance Abuse Treatment"],"published-print":{"date-parts":[[2022,8]]},"DOI":"10.1016\/j.jsat.2022.108776","type":"journal-article","created":{"date-parts":[[2022,3,25]],"date-time":"2022-03-25T12:45:00Z","timestamp":1648212300000},"page":"108776","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":33,"special_numbering":"C","title":["Long-acting injectable buprenorphine for opioid use disorder: A systematic review of impact of use on social determinants of health"],"prefix":"10.1016","volume":"139","author":[{"given":"Emily","family":"Martin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hayley","family":"Maher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gemma","family":"McKeon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sue","family":"Patterson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julie","family":"Blake","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kai Yang","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jsat.2022.108776_bb0005","series-title":"Diagnostic and statistical manual of mental disorders","year":"2013"},{"key":"10.1016\/j.jsat.2022.108776_bb0015","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1186\/s40985-018-0094-7","article-title":"Screening for social determinants of health in clinical care: Moving from the margins to the mainstream","volume":"39","author":"Andermann","year":"2018","journal-title":"Public Health Reviews"},{"key":"10.1016\/j.jsat.2022.108776_bb0020","doi-asserted-by":"crossref","DOI":"10.1016\/j.drugalcdep.2021.108959","article-title":"Tracing the affordances of long-acting injectable depot buprenorphine: A qualitative study of patients' experiences in Australia","volume":"227","author":"Barnett","year":"2021","journal-title":"Drug and Alcohol Dependence"},{"key":"10.1016\/j.jsat.2022.108776_bb0025","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1016\/j.jsat.2017.01.019","article-title":"Quality of life as an outcome of opioid use disorder treatment: A systematic review","volume":"76","author":"Bray","year":"2017","journal-title":"Journal of Substance Abuse Treatment"},{"issue":"1","key":"10.1016\/j.jsat.2022.108776_bb0030","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1353\/cpr.2020.0007","article-title":"Trends in abstinence and retention associated with a medication-assisted treatment program for people with opioid use disorders","volume":"14","author":"Brunisholz","year":"2020","journal-title":"Progress in Community Health Partnerships: Research, Education, and Action"},{"key":"10.1016\/j.jsat.2022.108776_bb0035","series-title":"Analyzing qualitative data","year":"1994"},{"key":"10.1016\/j.jsat.2022.108776_bb0040","author":"Camarus"},{"key":"10.1016\/j.jsat.2022.108776_bb0045","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/j.drugalcdep.2017.10.007","article-title":"Treatment for opioid use and outcomes in older adults: A systematic literature review","volume":"182","author":"Carew","year":"2018","journal-title":"Drug and Alcohol Dependence"},{"key":"10.1016\/j.jsat.2022.108776_bb0050","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1016\/j.drugalcdep.2019.05.003","article-title":"Opioid agonist treatment reduces losses in quality of life and quality-adjusted life expectancy in heroin users: Evidence from real world data","volume":"201","author":"Chang","year":"2019","journal-title":"Drug and Alcohol Dependence"},{"issue":"2","key":"10.1016\/j.jsat.2022.108776_bb0055","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1097\/HRP.0000000000000075","article-title":"Medication-assisted treatment of opioid use disorder: Review of the evidence and future directions","volume":"23","author":"Connery","year":"2015","journal-title":"Harvard Review of Psychiatry"},{"issue":"9","key":"10.1016\/j.jsat.2022.108776_bb0060","first-page":"1","article-title":"Methadone and buprenorphine for the management of opioid dependence: A systematic review and economic evaluation","volume":"11","author":"Connock","year":"2007","journal-title":"Health Technology Assessment (Winchester, England)"},{"key":"10.1016\/j.jsat.2022.108776_bb0065","first-page":"9381346","article-title":"Successful treatment of opioid dependence with flexible doses of injectable prolonged release buprenorphine","volume":"2019","author":"D'Agnone","year":"2019","journal-title":"Case Reports in Psychiatry"},{"issue":"10208","key":"10.1016\/j.jsat.2022.108776_bb0070","doi-asserted-by":"crossref","first-page":"1560","DOI":"10.1016\/S0140-6736(19)32229-9","article-title":"Global patterns of opioid use and dependence: Harms to populations, interventions, and future action","volume":"394","author":"Degenhardt","year":"2019","journal-title":"Lancet (London, England)"},{"issue":"3","key":"10.1016\/j.jsat.2022.108776_bb0075","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1016\/j.psym.2019.08.001","article-title":"Subcutaneous buprenorphine for a patient with a history of misusing an indwelling catheter: A case report","volume":"61","author":"Farahmand","year":"2020","journal-title":"Psychosomatics"},{"issue":"8","key":"10.1016\/j.jsat.2022.108776_bb0085","doi-asserted-by":"crossref","first-page":"1416","DOI":"10.1111\/add.14636","article-title":"Long-term safety of a weekly and monthly subcutaneous buprenorphine depot (CAM2038) in the treatment of adult out-patients with opioid use disorder","volume":"114","author":"Frost","year":"2019","journal-title":"Addiction (Abingdon, England)"},{"issue":"2","key":"10.1016\/j.jsat.2022.108776_bb0090","doi-asserted-by":"crossref","first-page":"e296","DOI":"10.1542\/peds.2014-2888","article-title":"Addressing social determinants of health at well child care visits: A cluster RCT","volume":"135","author":"Garg","year":"2015","journal-title":"Pediatrics"},{"key":"10.1016\/j.jsat.2022.108776_bb0095","doi-asserted-by":"crossref","first-page":"2123","DOI":"10.2147\/PPA.S180641","article-title":"Current and future options for opioid use disorder: A survey assessing real-world opinion of service users on novel therapies including depot formulations of buprenorphine","volume":"12","author":"Gilman","year":"2018","journal-title":"Patient Preference and Adherence"},{"key":"10.1016\/j.jsat.2022.108776_bb0100","doi-asserted-by":"crossref","first-page":"920","DOI":"10.1186\/1471-2458-14-920","article-title":"Offending, custody and opioid substitution therapy treatment utilisation among opioid-dependent people in contact with the criminal justice system: Comparison of indigenous and non-Indigenous Australians","volume":"14","author":"Gisev","year":"2014","journal-title":"BMC Public Health"},{"key":"10.1016\/j.jsat.2022.108776_bb9000","series-title":"National guidelines for medication-assisted treatment of opioid dependence","author":"Gowing","year":"2014"},{"issue":"3","key":"10.1016\/j.jsat.2022.108776_bb0110","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1016\/j.jsat.2013.10.004","article-title":"Leaving buprenorphine treatment: patients' reasons for cessation of care","volume":"46","author":"Gryczynski","year":"2014","journal-title":"Journal of Substance Abuse Treatment"},{"issue":"10173","key":"10.1016\/j.jsat.2022.108776_bb0115","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1016\/S0140-6736(18)32259-1","volume":"393","author":"Haight","year":"2019","journal-title":"Lancet (London, England)"},{"issue":"10","key":"10.1016\/j.jsat.2022.108776_bb0120","doi-asserted-by":"crossref","first-page":"1727","DOI":"10.1007\/s11136-011-9903-x","article-title":"Development and preliminary testing of the new five-level version of EQ-5D (EQ-5D-5L)","volume":"20","author":"Herdman","year":"2011","journal-title":"Quality of Life Research"},{"key":"10.1016\/j.jsat.2022.108776_bb0125","series-title":"Risk, safety, and clinical practice: Health care through the lens of risk","author":"Heyman","year":"2010"},{"key":"10.1016\/j.jsat.2022.108776_bb0130","series-title":"Social inequality: Forms, causes, and consequences","author":"Hurst","year":"2012"},{"issue":"7","key":"10.1016\/j.jsat.2022.108776_bb0135","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1080\/13696998.2017.1325744","article-title":"Use of opioid substitution therapies in the treatment of opioid use disorder: Results of a UK cost-effectiveness modelling study","volume":"20","author":"Kenworthy","year":"2017","journal-title":"Journal of Medical Economics"},{"key":"10.1016\/j.jsat.2022.108776_bb0140","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.drugalcdep.2015.12.021","article-title":"Opioid substitution therapy: Lowering the treatment thresholds","volume":"161","author":"Kourounis","year":"2016","journal-title":"Drug and Alcohol Dependence"},{"issue":"7","key":"10.1016\/j.jsat.2022.108776_bb0145","doi-asserted-by":"crossref","first-page":"1295","DOI":"10.1111\/add.14941","article-title":"Perceptions of extended-release buprenorphine injections for opioid use disorder among people who regularly use opioids in Australia","volume":"115","author":"Larance","year":"2020","journal-title":"Addiction (Abingdon, England)"},{"key":"10.1016\/j.jsat.2022.108776_bb0150","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1016\/j.jpsychires.2020.08.013","article-title":"Life expectancy of people who are dependent on opioids: A cohort study in New South Wales, Australia","volume":"130","author":"Lewer","year":"2020","journal-title":"Journal of Psychiatric Research"},{"issue":"6","key":"10.1016\/j.jsat.2022.108776_bb0155","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1097\/ADM.0000000000000517","article-title":"Patient-centered outcomes in participants of a buprenorphine monthly depot (BUP-XR) double-blind, placebo-controlled, multicenter, phase 3 study","volume":"13","author":"Ling","year":"2019","journal-title":"Journal of Addiction Medicine"},{"issue":"1","key":"10.1016\/j.jsat.2022.108776_bb0160","doi-asserted-by":"crossref","first-page":"129","DOI":"10.2147\/SAR.S38902","article-title":"The Treatment Effectiveness Assessment (TEA): An efficient, patient-centered instrument for evaluating progress in recovery from addiction","volume":"3","author":"Ling","year":"2012","journal-title":"Substance Abuse and Rehabilitation"},{"key":"10.1016\/j.jsat.2022.108776_bb0165","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jsat.2019.11.004","article-title":"Effects of monthly buprenorphine extended-release injections on patient-centered outcomes: A long-term study","volume":"110","author":"Ling","year":"2020","journal-title":"Journal of Substance Abuse Treatment"},{"issue":"5","key":"10.1016\/j.jsat.2022.108776_bb0170","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2021.9041","article-title":"Patient-reported outcomes of treatment of opioid dependence with weekly and monthly subcutaneous depot vs daily sublingual buprenorphine: A randomized clinical trial","volume":"4","author":"Lintzeris","year":"2021","journal-title":"JAMA Network Open"},{"issue":"6","key":"10.1016\/j.jsat.2022.108776_bb0175","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1001\/jamainternmed.2018.1052","article-title":"Weekly and monthly subcutaneous buprenorphine depot formulations vs daily sublingual buprenorphine with naloxone for treatment of opioid use disorder: A randomized clinical trial","volume":"178","author":"Lofwall","year":"2018","journal-title":"JAMA Internal Medicine"},{"issue":"12","key":"10.1016\/j.jsat.2022.108776_bb0180","doi-asserted-by":"crossref","first-page":"1868","DOI":"10.1038\/s41380-018-0094-5","article-title":"Effects of medication-assisted treatment on mortality among opioids users: A systematic review and meta-analysis","volume":"24","author":"Ma","year":"2019","journal-title":"Molecular Psychiatry"},{"key":"10.1016\/j.jsat.2022.108776_bb0185","series-title":"Social determinants of health","author":"Marmot","year":"2005"},{"issue":"1","key":"10.1016\/j.jsat.2022.108776_bb0190","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1097\/00005053-198001000-00006","article-title":"An improved diagnostic evaluation instrument for substance abuse patients. The Addiction Severity Index","volume":"168","author":"McLellan","year":"1980","journal-title":"The Journal of Nervous and Mental Disease"},{"issue":"2","key":"10.1016\/j.jsat.2022.108776_bb0195","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1080\/02791072.2015.1014948","article-title":"Changes in quality of life following buprenorphine treatment: Relationship with treatment retention and illicit opioid use","volume":"47","author":"Mitchell","year":"2015","journal-title":"Journal of Psychoactive Drugs"},{"issue":"7","key":"10.1016\/j.jsat.2022.108776_bb0200","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1000097","article-title":"Preferred reporting items for systematic reviews and meta-analyses: The PRISMA statement","volume":"6","author":"Moher","year":"2009","journal-title":"PLoS Medicine"},{"key":"10.1016\/j.jsat.2022.108776_bb0210","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.drugalcdep.2018.03.057","article-title":"Implants and depot injections for treating opioid dependence: Qualitative study of people who use or have used heroin","volume":"189","author":"Neale","year":"2018","journal-title":"Drug and Alcohol Dependence"},{"issue":"5","key":"10.1016\/j.jsat.2022.108776_bb0215","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1111\/dar.12939","article-title":"Depot buprenorphine injections for opioid use disorder: Patient information needs and preferences","volume":"38","author":"Neale","year":"2019","journal-title":"Drug and Alcohol Review"},{"issue":"1","key":"10.1016\/j.jsat.2022.108776_bb0220","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1186\/s12954-019-0296-4","article-title":"Prolonged-release opioid agonist therapy: Qualitative study exploring patients' views of 1-week, 1-month, and 6-month buprenorphine formulations","volume":"16","author":"Neale","year":"2019","journal-title":"Harm Reduction Journal"},{"issue":"6","key":"10.1016\/j.jsat.2022.108776_bb0225","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1037\/pha0000217","article-title":"Patient views of opioid pharmacotherapy biodelivery systems: Qualitative study to assist treatment decision making","volume":"26","author":"Neale","year":"2018","journal-title":"Experimental and Clinical Psychopharmacology"},{"key":"10.1016\/j.jsat.2022.108776_bb0230","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.drugalcdep.2017.12.043","article-title":"Rehospitalization and substance use disorder (SUD) treatment entry among patients seen by a hospital SUD consultation-liaison service","volume":"186","author":"Nordeck","year":"2018","journal-title":"Drug and Alcohol Dependence"},{"issue":"5","key":"10.1016\/j.jsat.2022.108776_bb0235","article-title":"Retention of patients in opioid substitution treatment: A systematic review","volume":"15","author":"O'Connor","year":"2020","journal-title":"PloS One"},{"issue":"5","key":"10.1016\/j.jsat.2022.108776_bb0240","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1080\/00952990701523698","article-title":"Quality of life among heroin users on buprenorphine versus methadone maintenance","volume":"33","author":"Ponizovsky","year":"2007","journal-title":"The American Journal of Drug and Alcohol Abuse"},{"issue":"9","key":"10.1016\/j.jsat.2022.108776_bb0250","doi-asserted-by":"crossref","first-page":"1647","DOI":"10.1111\/j.1360-0443.2011.03463.x","article-title":"Physical and mental health in severe opioid-dependent patients within a randomized controlled maintenance treatment trial","volume":"106","author":"Reimer","year":"2011","journal-title":"Addiction (Abingdon, England)"},{"issue":"10","key":"10.1016\/j.jsat.2022.108776_bb0255","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2016-012594","article-title":"Non-inferiority trials: Are they inferior? A systematic review of reporting in major medical journals","volume":"6","author":"Rehal","year":"2016","journal-title":"BMJ Open"},{"issue":"1","key":"10.1016\/j.jsat.2022.108776_bb0260","doi-asserted-by":"crossref","DOI":"10.1192\/bjo.2019.99","article-title":"Exploring psychological symptoms and associated factors in patients receiving medication-assisted treatment for opioid-use disorder","volume":"6","author":"Rosic","year":"2020","journal-title":"BJPsych Open"},{"key":"10.1016\/j.jsat.2022.108776_bb0265","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1016\/j.jsat.2020.01.009","article-title":"Perceptions and preferences for long-acting injectable and implantable medications in comparison to short-acting medications for opioid use disorders","volume":"111","author":"Saunders","year":"2020","journal-title":"Journal of Substance Abuse Treatment"},{"issue":"7","key":"10.1016\/j.jsat.2022.108776_bb0270","doi-asserted-by":"crossref","first-page":"1214","DOI":"10.1111\/add.14566","article-title":"Patterns of social determinants of health associated with drug use among women living with HIV in Canada: a latent class analysis","volume":"114","author":"Shokoohi","year":"2019","journal-title":"Addiction (Abingdon, England)"},{"issue":"6","key":"10.1016\/j.jsat.2022.108776_bb0275","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.02218-2018","article-title":"Letting the right one in: evaluating the generalisability of clinical trials","volume":"52","author":"Shrimanker","year":"2018","journal-title":"The European Respiratory Journal"},{"key":"10.1016\/j.jsat.2022.108776_bb0280","article-title":"RoB 2: A revised tool for assessing risk of bias in randomised trials","volume":"366","author":"Sterne","year":"2019","journal-title":"BMJ (Clinical Research Ed.)"},{"key":"10.1016\/j.jsat.2022.108776_bb0285","article-title":"ROBINS-I: A tool for assessing risk of bias in non-randomised studies of interventions","volume":"355","author":"Sterne","year":"2016","journal-title":"BMJ (Clinical Research Ed.)"},{"issue":"2","key":"10.1016\/j.jsat.2022.108776_bb0290","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1007\/s40471-019-00197-2","article-title":"Opioid use and intimate partner violence: A systematic review","volume":"6","author":"Stone","year":"2019","journal-title":"Currentent Epidemiology Reports"},{"issue":"1","key":"10.1016\/j.jsat.2022.108776_bb0295","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1111\/j.1360-0443.2007.02029.x","article-title":"The impact of treatment on 3 years' outcome for heroin dependence: Findings from the Australian Treatment Outcome Study (ATOS)","volume":"103","author":"Teesson","year":"2008","journal-title":"Addiction (Abingdon, England)"},{"key":"10.1016\/j.jsat.2022.108776_bb0300","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/j.jsat.2019.06.007","article-title":"Opioid users' willingness to receive prolonged-release buprenorphine depot injections for opioid use disorder","volume":"104","author":"Tompkins","year":"2019","journal-title":"Journal of Substance Abuse Treatment"},{"key":"10.1016\/j.jsat.2022.108776_bb0305","series-title":"User's manual for the SF-36v2 Health Survey","author":"Ware","year":"2008"},{"key":"10.1016\/j.jsat.2022.108776_bb0310","series-title":"Social determinants of health: The solid facts","year":"2003"},{"issue":"2","key":"10.1016\/j.jsat.2022.108776_bb0315","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1080\/14659891.2018.1523968","article-title":"\u201cA lot of people call it liquid handcuffs\u201d \u2013 Barriers and enablers to opioid replacement therapy in a rural area","volume":"24","author":"Wood","year":"2019","journal-title":"Journal of Substance Use"},{"key":"10.1016\/j.jsat.2022.108776_bb0320","series-title":"Guidelines for the psychosocially assisted pharmacological treatment of opioid dependence","year":"2009"},{"key":"10.1016\/j.jsat.2022.108776_bb0325","series-title":"Global health estimates 2016: Disease burden by cause, age, sex, by country and by region, 2000-2016","year":"2018"},{"key":"10.1016\/j.jsat.2022.108776_bb0330","series-title":"Social determinants of health","year":"2021"},{"issue":"11","key":"10.1016\/j.jsat.2022.108776_bb0335","doi-asserted-by":"crossref","first-page":"1493","DOI":"10.1080\/10826084.2016.1188946","article-title":"Outcomes of patients in long-term opioid maintenance treatment","volume":"51","author":"Zippel-Schultz","year":"2016","journal-title":"Substance Use & Misuse"}],"container-title":["Journal of Substance Abuse Treatment"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0740547222000587?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0740547222000587?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T19:58:37Z","timestamp":1760039917000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0740547222000587"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,8]]},"references-count":63,"alternative-id":["S0740547222000587"],"URL":"https:\/\/doi.org\/10.1016\/j.jsat.2022.108776","relation":{},"ISSN":["0740-5472"],"issn-type":[{"value":"0740-5472","type":"print"}],"subject":[],"published":{"date-parts":[[2022,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Long-acting injectable buprenorphine for opioid use disorder: A systematic review of impact of use on social determinants of health","name":"articletitle","label":"Article Title"},{"value":"Journal of Substance Abuse Treatment","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jsat.2022.108776","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"108776"}}